Precision BioSciences, Inc. (DTIL)
Largest Insider Buys in Sector
DTIL Stock Price History Chart
DTIL Stock Performance
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Insider Activity of Precision BioSciences, Inc.
Over the last 12 months, insiders at Precision BioSciences, Inc. have bought $81,308 and sold $131,927 worth of Precision BioSciences, Inc. stock.
On average, over the past 5 years, insiders at Precision BioSciences, Inc. have bought $101,155 and sold $1.97M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Germano Geno J (director) — $48,559. Kelly John Alexander (Chief Financial Officer) — $30,317. Brown Melinda (director) — $27,446.
The last purchase of 3,605 shares for transaction amount of $16,186 was made by Germano Geno J (director) on 2024‑12‑30.
List of Insider Buy and Sell Transactions, Precision BioSciences, Inc.
| 2024-12-30 | director | 3,605 0.0454% | $4.49 | $16,186 | +11.97% | |||
| 2024-12-27 | Chief Financial Officer | 2,113 0.0277% | $4.75 | $10,037 | +2.15% | |||
| 2024-12-27 | director | 4,320 0.0582% | $4.88 | $21,082 | +2.15% | |||
| 2024-12-26 | director | 3,016 0.0371% | $4.55 | $13,723 | 0.00% | |||
| 2024-11-21 | Chief Financial Officer | 3,000 0.0411% | $6.76 | $20,280 | -15.23% | |||
| 2024-11-04 | Sale | President and CEO | 3,012 0.0412% | $8.19 | $24,668 | -28.23% | ||
| 2024-11-04 | Sale | General Counsel and Secretary | 588 0.008% | $8.19 | $4,816 | -28.23% | ||
| 2024-06-10 | Sale | Chief Research Officer | 50 0.0007% | $11.79 | $590 | -26.60% | ||
| 2024-06-10 | Sale | General Counsel and Secretary | 93 0.0013% | $11.79 | $1,096 | -26.60% | ||
| 2024-05-02 | Sale | Chief Research Officer | 154 0.0021% | $10.32 | $1,589 | -13.38% | ||
| 2024-05-02 | Sale | President and CEO | 1,526 0.021% | $10.32 | $15,748 | -13.38% | ||
| 2024-05-02 | Sale | General Counsel and Secretary | 272 0.0037% | $10.32 | $2,807 | -13.38% | ||
| 2024-05-02 | Sale | Chief Medical Officer | 290 0.004% | $10.32 | $2,993 | -13.38% | ||
| 2024-05-01 | Sale | General Counsel and Secretary | 918 – | $0 | $0 | -10.31% | ||
| 2024-04-30 | Sale | Chief Medical Officer | 238 0.0033% | $10.03 | $2,386 | -9.79% | ||
| 2024-01-23 | Sale | Chief Research Officer | 28,000 0.0231% | $0.37 | $10,360 | +2554.44% | ||
| 2024-01-22 | Sale | President and CEO | 137,390 0.1111% | $0.36 | $49,460 | +2548.17% | ||
| 2024-01-22 | Sale | General Counsel and Secretary | 21,287 0.0172% | $0.36 | $7,663 | +2548.17% | ||
| 2024-01-22 | Sale | Chief Medical Officer | 21,526 0.0174% | $0.36 | $7,749 | +2548.17% | ||
| 2023-11-03 | Sale | President and CEO | 125,025 0.1021% | $0.40 | $50,010 | +2183.83% |
Insider Historical Profitability
| SMITH J. JEFFERSON | Chief Research Officer | 68559 0.8687% | $4.80 | 0 | 3 | |
| Kelly John Alexander | Chief Financial Officer | 40186 0.5092% | $4.80 | 8 | 0 | <0.0001% |
| Amoroso Michael | President and CEO | 28537 0.3616% | $4.80 | 0 | 6 | |
| Buehler Kevin | director | 8712 0.1104% | $4.80 | 1 | 0 | |
| Scimeca Dario | General Counsel and Secretary | 7969 0.101% | $4.80 | 0 | 9 | |
| Germano Geno J | director | 7807 0.0989% | $4.80 | 1 | 0 | |
| Brown Melinda | director | 7218 0.0915% | $4.80 | 1 | 0 | |
| List Alan | Chief Medical Officer | 4488 0.0569% | $4.80 | 0 | 6 | |
| JANTZ DEREK | Chief Scientific Officer | 4055174 51.3848% | $4.80 | 0 | 17 | |
| FMR LLC | 3738248 47.3689% | $4.80 | 1 | 0 | <0.0001% | |
| KANE MATTHEW R. | President and CEO | 2013597 25.5152% | $4.80 | 0 | 15 | |
| YAO TONY DUNG LING | director | 158003 2.0021% | $4.80 | 1 | 0 | <0.0001% |
| THOMSON DAVID S. | Chief Operating Officer | 111513 1.413% | $4.80 | 0 | 7 | |
| venBio Global Strategic Fund, L.P. | director | 50000 0.6336% | $4.80 | 1 | 0 | <0.0001% |
| Heery Christopher | Chief Medical Officer | 2485 0.0315% | $4.80 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Tang Capital Management, LLC | $7.99M | 8.51 | 589,569 | -82.66% | -$38.11M | 0.03 | |
| Janus Henderson | $7.74M | 8.27 | 573,052 | New | +$7.74M | <0.01 | |
| Perceptive Advisors | $6.52M | 6.94 | 480,483 | New | +$6.52M | <0.01 | |
| Spyglass Capital Management LLC | $5.23M | 5.57 | 385,440 | New | +$5.23M | 3.92 | |
| The Vanguard Group | $3.54M | 3.77 | 260,831 | -94.51% | -$60.94M | <0.0001 | |
| Alyeska Investment Group L P | $3.39M | 3.61 | 250,000 | New | +$3.39M | 0.02 | |
| Acadian Asset Management | $1.55M | 1.65 | 114,272 | -96.58% | -$43.75M | 0.01 | |
| Renaissance Technologies | $1.35M | 1.44 | 99,498 | -96.16% | -$33.78M | <0.01 | |
| Citadel Advisors LLC | $1.32M | 1.41 | 97,275 | -97.19% | -$45.68M | <0.01 | |
| Moloney Securities Asset Management Llc | $734,938.00 | 0.78 | 54,199 | -93.91% | -$11.34M | 0.11 | |
| Stifel | $540,650.00 | 0.58 | 39,871 | -97.42% | -$20.42M | <0.01 | |
| Geode Capital Management | $404,767.00 | 0.43 | 29,843 | -96.67% | -$11.74M | <0.0001 | |
| Bank of America | $385,280.00 | 0.41 | 28,413 | -96.7% | -$11.29M | <0.0001 | |
| BlackRock | $358,011.00 | 0.38 | 26,402 | -97.64% | -$14.82M | <0.0001 | |
| Tejara Capital Ltd | $335,841.00 | 0.36 | 24,767 | -96.67% | -$9.74M | 0.11 | |
| Blue Owl Capital Holdings Lp | $274,183.00 | 0.29 | 20,220 | -96.67% | -$7.95M | 0.02 | |
| Ci Private Wealth Llc | $161,106.00 | 0.17 | 11,881 | -94.78% | -$2.92M | <0.0001 | |
| Morgan Stanley | $159,452.00 | 0.17 | 11,759 | -96.48% | -$4.37M | <0.0001 | |
| Ubs Oconnor Llc | $156,564.00 | 0.17 | 11,546 | -95.15% | -$3.07M | 0.01 | |
| GOLDEN CAPITAL MANAGEMENT LLC | $153,676.00 | 0.16 | 11,333 | New | +$153,676.00 | <0.01 | |
| Gsa Capital Partners Llp | $137,000.00 | 0.15 | 10,067 | New | +$137,000.00 | 0.01 | |
| JPMorgan Chase | $115,476.00 | 0.12 | 8,516 | -96.49% | -$3.18M | <0.0001 | |
| Amundi | $91,345.00 | 0.12 | 8,521 | -96.67% | -$2.65M | <0.0001 | |
| Allworth Financial Lp | $64,668.00 | 0.07 | 4,769 | -96.67% | -$1.88M | <0.0001 | |
| Vivo Capital | $63,395.00 | 0.07 | 4,675 | -96.67% | -$1.84M | 0.01 | |
| Barclays | $39,000.00 | 0.04 | 2,873 | -98.66% | -$2.87M | <0.0001 | |
| Advisor Group Holdings Inc | $25,695.00 | 0.03 | 1,895 | -95.77% | -$581,168.02 | <0.0001 | |
| Wells Fargo | $11,674.00 | 0.01 | 861 | -88.86% | -$93,107.27 | <0.0001 | |
| Tower Research Capital | $5,275.00 | 0.01 | 389 | New | +$5,275.00 | <0.0001 | |
| Zurich Cantonal Bank | $4,787.00 | 0.01 | 353 | -96.77% | -$143,243.86 | <0.0001 | |
| UBS | $2,793.00 | <0.01 | 206 | -99.77% | -$1.2M | <0.0001 | |
| Newedge Advisors Llc | $644.00 | <0.01 | 48 | -98.2% | -$35,084.58 | <0.0001 | |
| Toth Financial Advisory Corp | $1,356.00 | <0.01 | 100 | New | +$1,356.00 | <0.0001 | |
| GPS Wealth Strategies Group LLC | $14.00 | <0.01 | 1 | New | +$14.00 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 9 | -93.75% | -$0 | <0.0001 | |
| Fidelity Investments | $27.00 | <0.01 | 2 | New | +$27.00 | <0.0001 | |
| Investors Research Corp | $108.00 | <0.01 | 8 | -96.8% | -$3,267.00 | <0.0001 | |
| Ameliora Wealth Management Ltd | $447.00 | <0.01 | 33 | -96.7% | -$13,098.45 | <0.0001 | |
| Citigroup | $14.00 | <0.01 | 1 | -100% | -$653,044.00 | <0.0001 | |
| Tsfg Llc | $0 | <0.01 | 3 | -97% | -$0 | <0.0001 | |
| Qube Research & Technologies | $68.00 | <0.01 | 5 | -98.05% | -$3,413.60 | <0.0001 |